BioLine Rx (NASDAQ:BLRX) is preparing to release its quarterly earnings on Thursday, 2025-08-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect BioLine Rx to report an earnings per share (EPS) of $-0.46.
Anticipation surrounds BioLine Rx's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Performance in Previous Earnings
Last quarter the company beat EPS by $1.06, which was followed by a 2.99% increase in the share price the next day.
Here's a look at BioLine Rx's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -1.06 | 0 | -0.10 | -0.14 |
| EPS Actual | 0 | 0 | -0.07 | 0 |
| Price Change % | 3.0% | -1.0% | 2.0% | 9.0% |
Tracking BioLine Rx's Stock Performance
Shares of BioLine Rx were trading at $3.75 as of August 12. Over the last 52-week period, shares are down 85.99%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for BioLine Rx visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.